Effective response to crizotinib of concurrent <i>KIF5B-MET </i>and <i>MET</i>-<i>CDR2-</i>rearranged non-small cell lung cancer: A case report
Lian-Fang Liu, Jia-Ying Deng, Analyn Lizaso, Jing Lin, Si Sun
Abstract
BACKGROUND: fusions. CASE SUMMARY: . Crizotinib was initiated at a dose of 250 mg twice daily. Within 4 wk of crizotinib therapy, repeat computed chromatography revealed a dramatic reduction in primary and metastatic lesions, assessed as partial response. She continued to benefit from crizotinib for 3 mo until disease progression and died within 1 mo despite receiving nivolumab therapy. CONCLUSION: . Crizotinib can serve as a therapeutic option for patients with MET fusions. In addition, our case also highlights the importance of comprehensive genomic profiling particularly in patients with no classic driver mutation for guiding alternative therapeutic decisions.
Topics & Concepts
CrizotinibMedicineLung cancerOncologyTargeted therapyInternal medicineCancer researchCancerMalignant pleural effusionLung Cancer Treatments and MutationsPancreatic and Hepatic Oncology ResearchCholangiocarcinoma and Gallbladder Cancer Studies